RxDoctor Payments Data

Amy Makemson, MD

Family Medicine · Huntsville, ALNPI 1790768976

Payments from drug & device makers

$12,906in general payments, 2019–2025

Across 796 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$982
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$542
  • Takeda Pharmaceuticals U.S.A., Inc.$438
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,74099%
  • Education$1661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)144$2,483
Novo Nordisk140$1,640
Lilly USA, LLC66$1,179
AstraZeneca55$982
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$542
Takeda Pharmaceuticals U.S.A., Inc.28$438
Astellas Pharma US Inc18$393
Pfizer20$359
GSK20$322
Axsome Therapeutics, Inc.16$273
Boehringer Ingelheim15$246
Abbott11$220
Eisai Inc.17$219
Biohaven Pharmaceutical Holding Company Ltd.8$217
Otsuka America Pharmaceutical, Inc.10$217
Merck14$206
Supernus Pharmaceuticals, Inc.11$200
Amgen11$190
Sunovion Pharmaceuticals Inc.18$156
Johnson & Johnson9$156
Kowa Pharmaceuticals America, Inc.10$152
Corium, LLC7$145
Vanda Pharmaceuticals Inc.8$140
Exact Sciences7$136
Adlon Therapeutics L.p.7$110
Currax Pharmaceuticals LLC7$107
Lundbeck LLC5$101
Amarin Pharma, Inc.7$101
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$92
Bayer5$87
Bausch Health US, LLC5$83
Tris Pharma Inc5$77
IBSA Pharma Inc.4$75
Harmony Biosciences LLC2$61
Sanofi Pasteur Inc.3$59
Idorsia Pharmaceuticals US Inc3$48
Neos Therapeutics, LP3$48
Corcept Therapeutics2$47
Genentech USA, Inc.3$43
Daiichi Sankyo Inc.2$41
Tolmar, Inc.2$37
Sumitomo Pharma America, Inc.2$36
Vivus LLC2$34
Nalpropion Pharmaceuticals LLC2$32
E.r. Squibb & Sons, L.L.C.2$31
Phathom Pharmaceuticals, Inc.2$29
AMAG Pharmaceuticals, Inc.2$26
Teva Pharmaceuticals USA, Inc.2$25
Noven Therapeutics, LLC1$25
Jazz Pharmaceuticals Inc.1$22
Dexcom, Inc.1$21
Novartis1$21
Paratek Pharmaceuticals, Inc.1$20
Ironwood Pharmaceuticals, Inc1$19
Almatica Pharma LLC1$19
Acella Pharmaceuticals, LLC1$18
Biohaven Pharmaceuticals, Inc.1$18
Aytu Biopharma, Inc.1$16
Amryt Pharma Holdings Ltd1$16
Antares Pharma, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,906 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$69,583
Medicare patients
203
Services billed
1,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide57$58,977
EliquisApixaban72$53,561
OzempicSemaglutide51$49,111
TrulicityDulaglutide43$46,848
Repatha SureclickEvolocumab71$42,343
RexultiBrexpiprazole17$30,721
XareltoRivaroxaban37$29,924
JardianceEmpagliflozin27$21,765
FarxigaDapagliflozin Propanediol12$17,962
GemtesaVibegron11$10,726
MyrbetriqMirabegron12$6,825
Rosuvastatin Calcium324$5,327
Levothyroxine Sodium405$4,459
SynthroidLevothyroxine Sodium50$4,173
Estradiol132$4,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,179$105,825100 claims
PfizerEliquis$359$53,56172 claims
Novo NordiskOzempic$1,640$49,11151 claims
Otsuka America Pharmaceutical, Inc.Rexulti$217$30,72117 claims
Johnson & JohnsonXarelto$156$29,92437 claims
Boehringer IngelheimJardiance$246$21,76527 claims
AstraZenecaFarxiga$982$17,96212 claims
Sumitomo Pharma America, Inc.Gemtesa$36$10,72611 claims
Astellas Pharma US IncMyrbetriq$393$6,82512 claims
AbbVieSynthroid$2,483$4,17350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →